Brain microvascular endothelial cells (BMECs) possess unique properties 34
(CD31) but lack EpCAM (CD326) and haematopoietic markers 125 (VECAD + PECAM1 + EpCAM -CD45 cells; Fig. 1c, d) . 126
Phase-contrast microscopy reveals that iBMECs exhibit a characteristic EC 127 morphology ( Fig. 1b, Extended Data Fig. 1a ; n = 5 biological replicates), however they 128 lack the canonical EC markers VECAD and PECAM1 by day 16 (Fig. 1c , Extended Data 129 6 Fig. 1b ; n = 5 biological replicates). Few iBMECs derived from hPSCs express low levels 130 of VECAD early during differentiation; however, they lose VECAD expression by day 16 131 ( Fig. 1c, d ; Extended Data Fig. 1b ). Moreover, the VECAD is not homogenously 132 distributed throughout the cell membrane in iBMECs. In contrast, the mesoendothelial-133 derived iECs, primary Human Umbilical Vein Endothelial Cells (HUVECs) and Brain 134
Microvascular Endothelial Cells (BMECs) express high levels of junctional VECAD and 135 PECAM1 (Fig 1c-d, Extended Data Fig. 1b ). Quantification of ECs by fluorescence 136 activated cell sorting (FACS) shows that the neuroendothelial differentiation protocol 137 yields on average 0.03±0.02%, 0.01±0.01%, 0.01±0.01%, VECAD + PECAM1 + marked 138 cells at day 11 and 0.13±0.07%, 0.02±0.01%, 0.03±0.015% VECAD + PECAM1 + marked 139 cells at day 16 (for H1, H6 and IMR90-4, respectively; Fig. 1d , e). We tested the in vivo 140 angiogenic potential of iBMECs using matrigel plugs implanted in immunocompromised 141 animals (NSG-SGM3, n=10 animals per cell line tested). Day 16 iBMECs derived from 142 H1, H6 or IMR90-4 fail to establish a vascular network compared to the bona fide 143 endothelial cells (HUVECs) (Extended Data Fig.1c-e ).
The poor yield of 144 VECAD + PECAM1 + in iBMECs is not due to the lack of endothelial "competence" from the 145 source cell lines (H1, H6 and IMR90-4), because they produce 3.23±2.41%, 4.43±1.47%, 146 8.70±2.78% VECAD + PECAM1 + iECs when differentiated with the mesoendothelial 147 protocol (H1, H6 and IMR90-4, respectively; Fig. 1d, f) . Upon purification by FACS on day 148 12, these iECs can be readily expanded (data not shown). These findings were compared 149 to primary human umbilical vein ECs (HUVECs) and brain microvascular ECs (BMECs), 150 which contain 97.17±0.98% and 83.37±4.028% VECAD + PECAM1 + cells ( Fig. 1d-f ). Thus, 151 8 population, while node #38 contains neuroendothelial iBMECs exclusively ( Fig. 2a, b) . 178
ECs are defined not only by their ability to form blood vessels, but also by expression of 179 unique transcription factors (TFs), signaling pathways and growth (angiocrine) factors 37-40 . 180 Using our unsupervised single cell RNA-seq analysis, we curated a list of essential genes 181 associated with EC identity that are highly expressed by cell clusters a-e from Fig. 2a . 182
This supervised analysis revealed that iBMECs, independently of the cell line and the day 183 of differentiation tested, lack expression of EC transcription factors (ETS1, ETS2, ELK3, 184 ELF1, GATA2, FLI1, SOX17, SOX18) compared to mesoendothelial iECs and bona fide 185 adult endothelial cell controls (Fig. 3 ). iBMECs also lack general EC cell signaling 186 machinery, including VEGFR2 (VEGF pathway), ICAM2, Notch ligands (JAG1, JAG2, 187 NOTCH4, EGFL7) and NOS3 (Fig. 3 , Extended data Fig. 4,7) . Moreover, iBMECs lack 188 secreted or membrane-bound angiocrine factors inherent to EC identity, such as 189 ANGPT2, APLN, BMP4, BMP6, FGF2, IGFBP4 and IGFBP7 (Fig. 3 ). CNS ECs are 190 characterized by high levels of WNT/β-catenin signaling which is required to induce and 191 maintain BBB properties [41] [42] [43] [44] . We analyzed expression of WNT/β-catenin signaling 192 components in iBMECs and found that they express low levels of key receptors (FZD4, 193 LRP5/6) but lack downstream targets that are indicative of pathway activation (LEF1, 194 NKD1/2, AXIN2, SOX17) (Extended Data Fig. 5 ). Therefore, the neuroendothelial 195 differentiation protocol yields iBMECs cells that lack both phenotypic and molecular 196 signatures of both general EC lineage and the CNS endothelium. expression by day 27 (Fig. 6b, lower panel) . Moreover, EEF-279 enforced expression followed by TGF-β inhibition restores VECAD and PECAM1 proper 280 localization to cell junctions (Extended data Fig. 3b ). We inspected the quality of our 281 reprogramming strategy using single-cell RNA sequencing. Compared to untransduced 282 controls, day 11 EEF-iBMECs show tight association with iECs, HUVECs and primary 283 BMECs ( Fig. 6c-d) . A significant number of vascular genes (VECAD, PECAM1, CLND5 284 and SOX17) are upregulated in EEF-iBMECs compared to untransduced control iBMECs 285 ( Fig. 6c ). Expression levels of these EC genes are comparable to those from iECs, 286 HUVEC and primary BMECs cultured in vitro, supporting the notion that EEF-iBMECs 287 have an endothelial identity. Moreover, angiocrine factors that regulate EC function 40 288 such as BMPs and Notch ligands are all expressed in EEF-iBMECs ( Fig. 6c ). In 289 conclusion, genome-wide, single-cell RNA sequencing analyses demonstrate that forced 290 expression of ETV2, FLI1 and ERG1 in conjunction with TGF-β inhibition reprograms 291 neuroectodermal epithelial cells into endothelial cells while silencing non-vascular genes, 292 strengthening our assertion that the chemically defined neuroendothelial differentiation 293 protocol 10, 18, 29 annotation of these unbiased cell clusters with their corresponding sample identities, we 311 conclude that batch effect and starting cell line are not the main source of variance in 312 these results. Moreover, bulk RNA sequencing, which has a greater depth of sequencing, 313 confirms the identity of the iBMECs obtained from our single cell RNA sequencing data. In 314 an unbiased analysis using bulk RNA seq data, our iBMECs were found to have nearly 315 identical global gene expression profiles as cells generated from the neuro-endothelial co-316 differentiation in several previous studies 10, 18, 29 . These findings substantiate our 317 conclusions that the published neuroendothelial protocol is working in our hands. The 318 same analysis also shows a primary BMEC control from the same previously published 319 dataset which closely clusters with our primary EC controls, allowing us to conclude that 320 sequencing bias and batch effect do not account for any major differences in the assigned 321 cell identities. Despite the presence of "BBB-like" properties such as the presence of tight 322 junction proteins, ability to form a high TEER and expression of several transporters due 323 to their epithelial nature, iBMECs cannot be used as an in vitro model of the human BBB 324 for future studies. 325
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We have not shown, however, that iBMECs are definitive hPSC-derived 326 neuroectodermal epithelial-like cells (NE-EpiCs), since they harbor many, but not all 327 attributes of an epithelial lineage present in the CNS. We demonstrate that constitutive 328 overexpression of ETS factors (FLI1, ERG, ETV2) using lentiviral vectors during the 329 specification phase, reprograms NE-EpiCs towards an EC identity as demonstrated by an 330 EPCAM -PECAM1 + VECAD + phenotype. Although these cells may not represent definitive 331 BBB-forming CNS ECs, the EEF-iBMECs have a more valid EC identity than the iBMECs 332 currently in use as an in vitro BBB model. These reprogrammed cells have both the 333 capacity to be passaged and expand in vitro, while retaining their PECAM1 + VECAD + EC 334 phenotype. We believe that this is a crucial step towards de novo generation of true BBB-335 forming CNS ECs for suitable in vitro modeling of physiological and pharmaceutical 336 studies which remains a major issue with the current iBMECs. Therefore, while 337 neuroendothelial differentiation of human iPCS to BMECs is rare, overexpression of ETS 338 transcription factors may promote conversion into vascular cells that are capable to form 339 barrier properties. 340
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Methods 341
Maintenance of hPSCs and neuroendothelial co-differentiation to iBMECs 342
These protocols were precisely followed as described previously 10, 28, 29 . All 343 reagents were procured based on these protocols, and each step and duration for 344 differentiation was followed rigorously. IMR90-4 and H6 iPSCs and H1 hESCs were 345 maintained between passages 20-42 on Matrigel (BD Biosciences, 354277) in mTeSR1 346 or TeSR-E8 medium (STEMCELL Technologies, 85850, 05990). For differentiation, cells 347 were passaged onto Matrigel in mTeSR1 or StemFlex (Gibco, A3349401) medium and 348 allowed to expand for 3 days. Cultures were then switched to unconditioned medium 349 (UM) lacking bFGF for 6 days. EC medium consisting of human endothelial serum-free 350 medium (hESFM; Gibco, 11111044) supplemented with 20 ng/mL bFGF (Peprotech, 100-351 18B), 1% platelet-poor plasma-derived bovine serum (Alfa Aesar, J64483AE), and 10 μM 352 all-trans retinoic acid (Sigma, R2625) was then added for an additional 2 days. Cells were 353 then dissociated with Accutase (Invitrogen, 00-4555-56) and plated onto 6-well 354 polystyrene plates or 1.12 cm 2 Transwell-Clear permeable inserts (0.4 mm pore size) in 355 EC media. Culture plates were coated with a mixture of Collagen IV (400 mg/mL; Sigma, 356 C6745) and Fibronectin (100 mg/ mL; Sigma, F1141) in H 2 O for at least 30 min at 37°C, 357 whereas inserts were incubated for a minimum of 4 h at 37°C. The resulting purified 358 hPSC-derived iBMECs were then grown in EC medium for 24 h, after which RA was 359 removed and cells were cultured until the indicated experimental timepoints. 360 361 PSC mesoendothelial differentiation to iECs 362 hPSC were maintained exactly as described above. Embryoid bodies were 363 generated and cultured in base hPSC medium consisting of StemPro-34 (Gibco, 364 16 10639011), nonessential amino acids (Gibco, 11140050), glutamine (Gibco, 35050061) , 365 penicillin/streptomycin/amphotericin B (Gibco, 15240096), β-mercaptoethanol 366 (MilliporeSigma, M3148) for 24 hours before the start of differentiation and the protocol 367 was carried out as previously described 31 . Medium is changed every 2 days for the 368 duration of the differentiation. Addition of 20 ng/ml BMP-4 (R&D Systems, 314-BP-05/C) 369 on day 0 (removed on day 7); on day 1, medium is supplemented with 10 ng/ml activinA 370 (STEMCELL technologies, 78001; removed at day 4); on day 2, medium is further 371 supplemented with 8 ng/ml FGF-2 (Peprotech, 100-18B; remained for the duration of 372 culture); on day 4, embryoid bodies are transferred to adherent conditions on Matrigel-373 coated plates and medium was supplemented with 25 ng/ml VEGF-A (Peprotech, 374 remained for the duration of culture) to specify vascular progenitors; on day 7, SB431542 375 (R&D Systems, 1614; TGFβ signaling inhibitor) is added at 10 μ M concentration and 376 remained for indicated duration to expand terminally differentiated endothelial cells (iECs) 377 378 Directing hPSC neuroendothelial co-differentiation towards EEF-iBMECs 379 IMR90-4, H6, and H1 hPSCs were differentiated according to the Neuro-380
Endothelial co-differentiation protocol as described previously 34 . Following the 6 days of 381 differentiation in UM, cells were transduced via lentiviral vectors for ETS transcription 382 factors FLI1, ERG, ETV2 and cultured in EC medium, exactly as mentioned above. No 383 further changes were made to the protocol because the cells were terminally cultured. 384 385
Single-cell RNAseq digital droplet sequencing (ddSeq) 386
A single-cell suspension was loaded into the Bio-Rad ddSEQ Single-Cell Isolator 387 on which cells were isolated, lysed and barcoded in droplets. Droplets were then 388 disrupted and cDNA was pooled for second strand synthesis. Libraries were generated 389 with direct tagmentation followed by 3' enrichment and sample indexing using Illumina 390 Nextera library prep kit. Pooled libraries were sequenced on the Illumina NextSeq500 391 sequencer. Sequencing data were primarily analyzed using the SureCell RNA Single-Cell 392
App in Illumina BaseSpace Sequence Hub. 393
All single cell analyses were performed using the Seurat package in R (version 394 2.3.4). UMI counts files that had been knee-filtered were downloaded from the Illumina 395
BaseSpace Sequence Hub. After initial quality control, cells that were included in the 396 analysis were required to have a minimum 900 genes expressed and a maximum 5500 397 genes expressed, in addition to a minimum 1100 UMIs. This resulted in a total 20,069 398 cells passing quality filters across the 18 samples as seen in Extended Data Figure 2b . 399
Following best practices in the package suggestions UMI counts were log-normalized and 400 after the most highly variable genes selected the data matrices were scaled using a linear 401 model with variation arising from UMI counts mitigated for. Principal component analysis 402 was subsequently performed on this matrix and after reviewing principal component 403 heatmaps and jackstraw plots t-distributed stochastic neighbor embedding analysis 404 (tSNE) visualization were performed on the top 40 components and clustering resolution 405 was set at 1.0 for visualizations. Differential gene expression for gene marker discovery 406 across the clusters were performed using the Wilcoxon rank sum test as used in the 407 Seurat package. 408
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Immunofluorescence 410
Fixed Samples: Cells were fixed with 4% paraformaldehyde for 15 minutes prior to 411 staining. To prevent non-specific binding of the primary antibody, samples were blocked 412 18 with 5% horse serum in PBS solution for 60 minutes. Cells were washed 3 times in PBS 413 and dilute primary antibody in 5% horse serum was added according to manufacturer's 414 recommended concentration and left overnight at 4ºC. If the protein was intracellular, 415 permeabilization using 0.2% Triton X-100 was necessary during block and staining with 416 primary antibody. After staining with primary antibody, cells were incubated with 417 secondary antibody in 5% horse serum for 1 hour at room temperature on a shaker. 418
Following a thorough wash to remove unbound secondary antibody, DAPI was used at 1 419 µg/ml to stain nuclei. 420
Live Samples: Human IgG antibody was used at 1:50 in PBS with 0.5% BSA and 421 2 mM EDTA to block F c receptors prior to staining. The blocked cells were stained for 30 422 minutes at 4°C with fluorochrome-conjugated antibodies according to the 423 manufacturer's recommendations. Stained cells were washed in PBS to prevent 424 saturation of the fluorescent dye during imaging. All imaging was performed using a 425
Zeiss 710 META confocal microscope. 426 427
Flow cytometry 428
Before staining, F c receptors were blocked with human IgG antibody at 1:50 429 Total RNA, greater than 100ng, from cultured cells was isolated in TRIzol L and 441 purified using Qiagen RNeasy Mini Kit per manufacturer's protocols. Agilent Technologies 442
2100 Bioanalyzer was used to assess the RNA quality. RNA libraries were prepared and 443 multiplexed using Illumina TruSeq RNA Library Preparation Kit v2 (non-stranded and 444 poly-A selection) and 10 nM of cDNA was used as the input for high-throughput 445 sequencing via Illumina's HiSeq 2500 platform, producing 50 bp paired end reads. Paired 446 end sequencing reads were then quality-checked and trimmed where appropriate using 447 Trimmomatic 0.36 49 and the resultant filtered reads reads were mapped to the human 448 reference genome GRCh38 using STAR aligner 50 . Aligned bam files were subsequently 449 sorted and raw transcript counts were quantified using HTSeq 51 to produce counts 450 matrices based off the human reference transcriptome for GRCh38. Previously published 451
RNAseq data for hPSC derived iBMECs and primary BMECs were downloaded from the 452 Gene Expression Omnibus (GEO, GSE97575) 18 along with previously published data for 453
HUVECs and LSECs (GEO, GSE40291) 52 and were processed in the same way as for 454 the bulk RNAseq libraries prepared for the experiment. Raw counts were processed in R 455 package edgeR 53 and a Log2 counts per million matrix was calculated after filtering and 456 quality control. A heatmap displaying the 500 most variable genes was subsequently 457 formulated with the distance between both rows and columns being calculated via 458
Euclidean distance and with dendrograms computed and reordered based on row and 459 column means. 460 20 461
In vivo tubulogenesis assay 462 H1, H6, and IMR90-4 derived neuroendothelial iBMECs at day 16 of differentiation 463 and primary HUVECs were resuspended in Matrigel (Corning, 254277) at 464 500,000cells/300μL and injected subcutaneously into immunocompromised mice (NSG-465 SGM3; Jax, 013062). Mice were also injected with an empty Matrigel control. After 5 466 days, mice were sacrificed following institutional guidelines and solidified Matrigel plugs 467 were excised and fixed using 4% paraformaldehyde (Alfa Aesar, AA43368-9M). Plugs 468 were cryosectioned, stained using CD144 (BV9, Biolegend), Agglutinin 1 (UEA1, Vector 469 Labs), and EPCAM (9C4, Biolegend). Slides were fixed using Fluoroshield with DAPI 470 (Sigma-Aldrich, F6057) and imaging was performed using a Zeiss 710 META confocal 471 microscope. Quantification analysis of images were conducted using Angiotool 54 . 472 473
Virus production 474
Human ETV2, FLI1, and ERG lentiviral particles were generated and tittered as 475 described in Ginsberg et al., with the following modifications. 293T Lenti-X cells (passage 476 8-10; subconfluent) were used to produce lentiviral particles using Lenti-X packaging 477 single-shot system, following the manufacturer's protocol. Filter through a 0.45μm PES 478 filter attached to a 30ml syringe and use Lenti-358 X concentrator following 479 PLVAP  CD34  SOX17  CLDN5  ICAM2  SOX18  TAL1  ROBO4  PECAM1  GJA4  DLL4  AQP1  ERG  MFNG  ESAM  RASIP1  FLT4  NOTCH4  NOS3  BMP6  ANGPT2  KIT  E2F5  FGF2  JAG2  GATA2  BMP4  CDH5  ENG  EGFL7  PROCR  KDR  BMP2  MEF2C  FLT1  PTPRB  FLI1  CXCL14  FREM2  EPCAM  NPPB  KCNK1  SPP1  SERPINF1  TAGLN  KRT18  SCD  KRT8  KRT19  KRT7  IGFBP7  IGFBP4  ETV6  ETS2  SLC12A2  ELF1  ID3 FZD7  FZD6  FZD5  FZD4  FZD3  FZD2  FZD10  FZD1  FRAT2  FRAT1  FOSL1  FBXW11  EP300  DVL3  DVL2  DVL1  DKK2  DKK1  DAAM2  DAAM1  CXXC4  CUL1  CTNNBIP1  CTNNB1  CTBP2  CTBP1  CSNK2B  CSNK2A2  CSNK2A1  CSNK1A1L  CSNK1A1  CREBBP  CHP2  CHD8  CCND3  CCND2  CCND1  CAMK2G  CAMK2D  CAMK2B  CAMK2A  CACYBP  BTRC  AXIN2  AXIN1  APC2  APC   PRKCB  PRKCA  PRKACB  PRKACA  PRICKLE2  PRICKLE1  PPP3R2  PPP3R1  PPP3CC  PPP3CB  PPP3CA  PPP2R5E  PPP2R5D  PPP2R5C  PPP2R5B  PPP2R5A  PPP2R1B  PPP2R1A  PPP2CB  PPP2CA  PPARD  PORCN  PLCB4  PLCB3  PLCB2  PLCB1  NLK  NKD2  NKD1  NFATC4  NFATC3  NFATC2  NFATC1  NFAT5  MYC  MMP7  MAPK9  MAPK8  MAPK10  MAP3K7  LRP6  LRP5  LEF1  JUN  GSK3B  FZD9  FZD8   WNT9B  WNT7B  WNT7A  WNT6  WNT5B  WNT5A  WNT4  WNT3A  WNT3  WNT2B  WNT2  WNT16  WNT11  WNT10B  WNT10A  WIF1  VANGL2  VANGL1  TP53  TCF7L2  TCF7L1  TCF7  TBL1Y  TBL1XR1  TBL1X  SOX17  SMAD4  SMAD3  SMAD2  SKP1  SIAH1  SFRP5  SFRP4  SFRP2  SFRP1  SENP2  RUVBL1  ROCK2  ROCK1  RHOA  RBX1  RAC3  RAC2  RAC1  PSEN1 CTNNA2  CTNNA1  CSNK2B  CSNK2A2  CSNK2A1  CRB3  CLDN9  CLDN8  CLDN7  CLDN6  CLDN5  CLDN4  CLDN3  CLDN23  CLDN22  CLDN19  CLDN16  CLDN15  CLDN14  CLDN11  CLDN10  CLDN1  CGN  CDK4  CDC42  CASK  ASH1L  AMOTL1  AKT3  AKT2  AKT1  ACTN4  ACTN3  ACTN2  ACTN1  ACTG1  ACTB   MYL7  MYL5  MYL2  MYL12B  MYL12A  MYH9  MYH7B  MYH7  MYH6  MYH3  MYH15  MYH14  MYH11  MYH10  MRAS  MPP5  MPDZ  MLLT4  MAGI3  MAGI2  MAGI1  LLGL2  LLGL1  KRAS  JAM3  JAM2  INADL  IGSF5  HRAS  HCLS1  GNAI3  GNAI2  GNAI1  F11R  EXOC4  EXOC3  EPB41L3  EPB41L2  EPB41L1  EPB41   ZAK  YES1  VAPA  TJP3  TJP2  TJP1  TJAP1  SYMPK  SRC  SPTAN1  RRAS2  RRAS  RHOA  RAB3B  RAB13  PTEN  PRKCZ  PRKCQ  PRKCI  PRKCH  PRKCG  PRKCE  PRKCD  PRKCB  PRKCA  PPP2R2D  PPP2R2C  PPP2R2B  PPP2R2A  PPP2R1B  PPP2R1A  PPP2CB  PPP2CA  PARD6G  PARD6B  PARD6A  PARD3  OCLN  NRAS  MYLPF  MYL9 
